Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,283 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07697456RecruitingPhase 2
Study of advanced therapies for Crohn's or ulcerative colitis
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
Dothan, AlabamaAges 18–75 - NCT07071519RecruitingPhase 3
Risankizumab for young people with ulcerative colitis
This study tests risankizumab (a medication that targets inflammation) in young people with ulcerative colitis who haven't improved enough on other treatments. It aims to see if risankizumab can help control symptoms and reduce bowel inflammation.
Phoenix, ArizonaAges 2–17 - NCT07686120RecruitingPhase 3
Baxdrostat for uncontrolled high blood pressure
This trial tests a new medicine called baxdrostat for people whose blood pressure stays high even when they take two or more medicines. It will be added to your current blood pressure pills to see if it helps lower your blood pressure more.
BeijingAges 18 years+ - NCT07612878Recruiting
Registry tracking COPD patients starting dupilumab treatment
This is a registry—an observational study tracking patients with COPD (chronic lung disease) who are newly starting a medication called dupilumab. Researchers will follow your health outcomes to learn how well this treatment works in real-world practice.
Indianapolis, IndianaAges 40 years+ - NCT07785609RecruitingPhase 2
New drug combination for advanced solid tumors
This trial tests a new drug combination for people with advanced solid tumors. It aims to see if the combination is safe and may shrink tumors.
San Antonio, TexasAges 18 years+ - NCT07226986RecruitingPhase 1/Phase 2
Study of AMO959 with Lutetium-177 and ARPI for prostate cancer
This trial tests a new combination therapy for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It combines an experimental drug (AMO959) with a targeted radiation treatment (Lutetium-177) and a standard hormone therapy to see if it helps control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06820463RecruitingPhase 2
Study of telisotuzumab adizutecan plus chemo for metastatic colorectal cancer
This trial tests a new drug combination for people with metastatic colorectal cancer. The study includes an experimental antibody-drug conjugate (telisotuzumab adizutecan) plus standard chemotherapy and targeted therapies, to see if it works better than current options.
Duarte, CaliforniaAges 18 years+ - NCT05875168RecruitingPhase 1/Phase 2
Study of DS-3939a for Advanced Solid Tumors
This trial is testing a new drug called DS-3939a for people with advanced solid tumors that have not responded to other treatments. The study has two parts to find the right dose and see how well it works.
Sarasota, FloridaAges 18 years+ - NCT07754786RecruitingPhase 3
Comparing a new eczema medicine with dupilumab
This study tests whether a new biologic medicine (IBI3027) works as well as an approved medicine (dupilumab) for treating moderate-to-severe eczema. If you join, you may receive one of the two treatments, and researchers will compare their effects on your skin and itching.
Guangzhou, GuangdongAges 18–75 - NCT07600736RecruitingPhase 2
Safety study of ABS-1230 for children with KCNT1 epilepsy
This trial tests a new drug called ABS-1230 in children and young adults with KCNT1-related epilepsy, a rare genetic form of epilepsy. The study will check if the drug is safe and if it helps reduce seizures.
Hackensack, New JerseyAges 1 month–21 years - NCT07607964RecruitingPhase 1
ABBV-519 Study for Lupus or Rheumatoid Arthritis
This early-stage trial tests a new drug called ABBV-519 given as infusions or injections to treat systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in adults whose disease hasn't responded well to other treatments. Researchers will measure how safe the drug is, how it moves through your body, and whether it helps reduce symptoms.
Anniston, AlabamaAges 18–75 - NCT07318610RecruitingPhase 3
Study of a new blood thinner in people with leg artery disease
This trial tests if a new blood-thinning drug (factor XI inhibitor) can prevent serious heart and leg problems in people who recently had a leg artery procedure. It compares the new drug to standard care for up to 3 years.
Alexander City, AlabamaAges 18 years+ - NCT06975865RecruitingPhase 3
Rilzabrutinib for sickle-cell disease pain episodes
This study tests an oral medicine called rilzabrutinib to see if it can reduce painful episodes in people with sickle-cell disease. It may be an option if you have regular pain crises and are looking for a new treatment.
Birmingham, AlabamaAges 10–65 - NCT07684599RecruitingPhase 3
Maintenance treatment for advanced endometrial cancer
This study tests a new maintenance therapy (mocertatug rezetecan) to help keep endometrial cancer from coming back after initial chemotherapy and immunotherapy. It may help people whose cancer had a good response to first-line treatment.
FukuokaAges 18 years+ - NCT06855277RecruitingPhase 3
AAA817 with hormone therapy for advanced prostate cancer
This trial tests a new combination treatment (AAA817 plus a hormone therapy) against standard care for men with advanced PSMA-positive prostate cancer that has spread and stopped responding to a previous hormone therapy. It may be an option if you haven't had certain prior treatments.
Homewood, AlabamaAges 18–100 - NCT07825064RecruitingPhase 2
Cevostamab combination after CAR T-cell therapy for multiple myeloma
This trial tests a new drug, cevostamab, combined with two standard medicines (pomalidomide and dexamethasone) for people with multiple myeloma who have already had CAR T-cell therapy. It aims to see if this combination can help control the cancer better.
GreifswaldAges 18 years+ - NCT07214779RecruitingPhase 3
New drug vs chemo for platinum-resistant ovarian cancer
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
Anchorage, AlaskaAges 18 years+ - NCT07286266RecruitingPhase 3
Testing a new drug for platinum-resistant ovarian cancer
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
Randwick, New South WalesAges 18 years+ - NCT07344311RecruitingPhase 1
CAR-T cell therapy for advanced prostate cancer
This trial tests a new immunotherapy called A-CAR032, which uses your own immune cells to attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer that has progressed after other treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07498426RecruitingPhase 3
Study of NIO752 for progressive supranuclear palsy
This trial tests a new medicine called NIO752 for people with progressive supranuclear palsy (PSP), a condition that affects movement, balance, and thinking. The goal is to see if it can help slow the disease's progression.
Scottsdale, ArizonaAges 41–81 - NCT05263206RecruitingPhase 3
Shot medicine (dupilumab) for severe, unexplained chronic itching
This Phase 3 study tests whether dupilumab injections can reduce severe itching that has no clear cause. It also checks how safe the medicine is over the study period.
Bakersfield, CaliforniaAges 18–90 - NCT05765851RecruitingPhase 1
A study of a new drug for advanced solid tumors with HER2
This trial tests a new combination treatment for people with advanced solid tumors that have HER2 changes. The goal is to see if it can shrink tumors or slow growth.
Sarasota, FloridaAges 18 years+ - NCT04704297RecruitingPhase 4
Trigger point shots for low back muscle pain
This trial tests whether injecting sore “trigger points” in low back muscles helps improve chronic low back pain. It compares treatments in people with specific low back muscle pain patterns and excludes several other causes of pain.
Tacoma, WashingtonAges 18 years+ - NCT04833491Recruiting
Eye measurements before cataract surgery and vision quality after
This study uses very specific eye measurements done before cataract surgery to see how they relate to the clarity of vision after surgery. It may help surgeons choose the best surgical approach and improve visual outcomes.
HangzhouAges 2–90
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,283 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.